Skye Bioscience Inc
Change company Symbol lookup
Select an option...
SKYE Skye Bioscience Inc
SITE SiteOne Landscape Supply Inc
KO Coca-Cola Co
C Citigroup Inc
GPS Gap Inc
LHX L3harris Technologies Inc
TIVC Tivic Health Systems Inc
XGABX Gabelli Equity Trust Inc
LAZR Luminar Technologies Inc
SPOFF GoldSpot Discoveries Corp
Go

Health Care : Biotechnology |
Company profile

Skye Bioscience, Inc. is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. The Company’s products programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

Price
Delayed
$0.0579
Day's Change
-0.0003 (-0.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.058
Day's Low
0.0536
Volume
(Heavy Day)

Today's volume of 701,102 shares is on pace to be much greater than SKYE's 10-day average volume of 1,672,845 shares.

701,102

Company Profile

Skye Bioscience, Inc. is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. The Company’s products programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
3.35x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

No short interest available.

Share Information

SKYE is in a share class of common stock
Float
360.2M
Shares Outstanding
476.1M
Institutions Holding Shares
5
3.35%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Punit S. DhillonChmn.
  • Kaitlyn ArsenaultCFO
  • Tu DiepOther
  • Margaret Dalesandro
  • James Heppell

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.